今海医疗科技(02225)午后涨超41%，绩后累计涨幅已超80%。截至发稿，涨41.54%，报0.92港元，成交 额2485.59万港元。 消息面上，今海医疗科技近日发布中期业绩，集团收益1452.9万新加坡元，同比减少43.98%；股东应占 亏损1025.3万新加坡元，同比扩大69.67%。公司此前发布公告，拟1.2亿股新股，占扩大后股本约 2.27%。所得款项净额约为1.61亿港元，拟用于为潜在并购医疗保健相关项目及/或公司及投资医疗保健 相关产业提供资金；研发开支；及一般营运资金。 值得注意的是，7月2日，今海医疗科技的全资附属公司上海今海医疗科技有限公司与宁波戴维医疗 （300314）器械股份有限公司(300314.SZ)的全资附属公司宁波维尔凯迪医疗器械有限公司订立为期五 年的合作框架协议。根据该协议，上海今海与戴维医疗集团将致力于在国际市场上开展内窥镜产品的联 合合作，旨在打造在国际市场上具有竞争力的高端医疗器械解决方案。 ...

值得注意的是，7月2日，今海医疗科技的全资附属公司上海今海医疗科技有限公司与宁波戴维医疗器械 股份有限公司(300314.SZ)的全资附属公司宁波维尔凯迪医疗器械有限公司订立为期五年的合作框架协 议。根据该协议，上海今海与戴维医疗集团将致力于在国际市场上开展内窥镜产品的联合合作，旨在打 造在国际市场上具有竞争力的高端医疗器械解决方案。 智通财经APP获悉，今海医疗科技(02225)午后涨超41%，绩后累计涨幅已超80%。截至发稿，涨 41.54%，报0.92港元，成交额2485.59万港元。 消息面上，今海医疗科技近日发布中期业绩，集团收益1452.9万新加坡元，同比减少43.98%；股东应占 亏损1025.3万新加坡元，同比扩大69.67%。公司此前发布公告，拟1.2亿股新股，占扩大后股本约 2.27%。所得款项净额约为1.61亿港元，拟用于为潜在并购医疗保健相关项目及/或公司及投资医疗保健 相关产业提供资金；研发开支；及一般营运资金。 ...

Group 1 - The company reported a revenue of 155 million yuan for the first half of 2025, representing a year-on-year growth of 2.40% [1] - The net profit attributable to the parent company was 34.38 million yuan, with basic earnings per share of 0.76 yuan [1] - The net cash flow from operating activities improved significantly to 17.53 million yuan compared to the same period last year [1] Group 2 - The company emphasized its commitment to independent research and development, with R&D investment reaching 24.74 million yuan, a year-on-year increase of 7.52%, accounting for 15.96% of revenue [2] - The company completed 85 patent applications and received 74 authorized patents, including 21 invention patents [2] - The company has made progress in the field of flexible endoscopes by forming a specialized technical team to overcome core technological bottlenecks [2] Group 3 - The company aims to maintain its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, focusing on product iteration and brand promotion [3] - The company plans to enhance the flexibility of its R&D and marketing systems while improving operational processes and internal controls [3] - The company is committed to strengthening its core competitive advantages through effective supply chain management and product quality [3]

Core Insights - Xishan Technology achieved a total operating revenue of 155 million yuan in the first half of 2025, representing a year-on-year growth of 2.4%, and a net profit attributable to shareholders of 34.38 million yuan [1] - The company continues to adhere to its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, expanding its business lines while responding to changes in the economic environment and regulatory trends in the medical device industry [1] Group 1: R&D and Innovation - The company emphasizes independent R&D innovation, with R&D investment amounting to 24.74 million yuan, a year-on-year increase of 7.52%, accounting for 15.96% of total operating revenue [1][2] - A total of 85 patent applications were completed, with 74 patents granted during the reporting period, and the company added 2 Class III medical device registration certificates and 8 Class II medical device registration certificates [2] - The company is focusing on strategic projects for innovation breakthroughs and enhancing its competitive advantage in surgical power devices through strategic allocation of R&D resources and equipment iteration [2] Group 2: Production Capacity and Manufacturing - The company has significantly increased its production facility area with the full utilization of a new park, laying a hardware foundation for future capacity enhancement [2] - It is strengthening its core component production capabilities through automation and modular production, implementing a comprehensive traceability and data loop system from raw material intake to finished product delivery [2] Group 3: Market Expansion and Sales - The company is enhancing its end-sales channel construction by focusing on hospital user development, increasing user numbers, and boosting existing users' equipment and consumable usage to rapidly improve market share [3] - Xishan Technology has established a rich product matrix covering various departments such as neurosurgery, ENT, orthopedics, breast surgery, general surgery, and gynecology, providing comprehensive solutions for multiple scenarios [3] - The company is increasing its investment in international registration and promotion, expanding its overseas market presence, with products now covering 46 countries and regions as of the first half of 2025 [3]

Core Viewpoint - Recent research by Ningquan Asset on OFILM shows significant progress in various business segments, including smartphone, smart automotive, new fields, handheld imaging devices, and endoscope products [1] Group 1: Smartphone Business - OFILM's revenue in the smartphone sector increased year-on-year, driven by advancements in multi-group lens alignment technology and miniaturized module packaging technology [1] - Innovative products such as floating macro modules and periscope long-focus macro modules have achieved mass production [1] - Future upgrade directions in the smartphone optical industry include larger optical sensors, widespread adoption of periscope long-focus modules, and the extensive use of glass-plastic hybrid lenses [1] Group 2: Smart Automotive Sector - The company's revenue in the smart automotive sector grew by 18.19% year-on-year [1] - Continuous innovation in onboard cameras, lenses, and system-level solutions is evident, covering various camera types and LiDAR receiving modules [1] Group 3: New Fields and Handheld Imaging Devices - Revenue from new fields increased by 9.73%, with a gross margin of 14.64%, indicating improved profitability [1] - In the handheld imaging device sector, the company has accumulated deep expertise in technology research and development, mass production processes, and quality management, leading to superior yield and reliability of camera module products [1] Group 4: Endoscope Products - The urinary system endoscope module has entered mass production, while modules for the digestive and respiratory systems are expected to begin mass production in the second half of the year [1] - These products are characterized by miniaturization, stable resolution, and high definition [1]